참고문헌
- Carter D, Greenson JK, Reuter VE, et al (2010). Sternberg's Diagnostic Surgical Pathology, Eds Mills SE. Lippincott Williams Wilkins, Philadelphia, 1757.
- Cho DS, Joo HJ , Oh DK, et al (2005). Cyclooxygenase-2 and P53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J, 46, 133-140. https://doi.org/10.3349/ymj.2005.46.1.133
- Dirim A, Haberal AN, Goren MR, et al (2008). VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value. Int Urol Nephrol, 40, 861-868. https://doi.org/10.1007/s11255-008-9362-7
- Dubois RN, Abramson SB, Crofford L, et al (1998). Cyclooxygenase in biology and disease. FASEB J, 12, 1063-73. https://doi.org/10.1096/fasebj.12.12.1063
- Hasan G, Elife S, Aysenur AI, et al (2009). COX-2 expression and microvessel density in clear cell type renal cell carcinoma. Turk Pathologi Dergisi, 25, 13-19.
- Hashimoto Y, Kondo Y, Kimura G, et al (2004). Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathol, 44, 353-359 https://doi.org/10.1111/j.1365-2559.2004.01853.x
- Kankuri-Tammilehto MK, Soderstrom KO, Pelliniemi TT, et al (2010). Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res, 30, 3023-3030.
- Kumar V, Abbas AK, Fausto N, Aster J (2010). Robbins and Cotran Pathologic Basis of Disease. Elsevier, Philadelphia, 964-6.
- Lee JW, Park JH, Suh JH, et al (2012). Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma. Korean J Pathol, 46, 237-45. https://doi.org/10.4132/KoreanJPathol.2012.46.3.237
- Miyata Y, koga S, Kanda S, et al (2003). Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res, 9, 1741-1749
- Mungan Mu, Gurel D, Canda AE, et al (2006).Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia and renal cell carcinoma. Eur Urol, 50, 92-7. https://doi.org/10.1016/j.eururo.2005.12.039
- Rosai J (2011). Rosai and Ackerman Surgical Pathology. Elsevier, Philadelphia, 1183-93.
- Schwandt A, Garcia J.A, Elson P, et al (2011). Clinical and immunomodulatory effects of celecoxib plus interferonalpha in metastatic renal cell carcinoma patient with COX-2 tumor immunostaining. J Clin Immunol, 31, 690-8 https://doi.org/10.1007/s10875-011-9530-x
- Sozen S, Gurocak S, Erdem O, et al (2008). Cyclooxygenase-2 expression: Does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma. Int Urol Nephrol, 40, 295-301. https://doi.org/10.1007/s11255-007-9268-9
- Sun H, Wang H , Qin WJ, et al (2009). Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 25, 384-50.
-
Tawfik OW, Kramer B, Shideler B, et al (2007). Prognostic Significance of CD44, Platelet-Derived Growth Factor Receptor
${\alpha}$ , and Cyclooxygenase 2 Expression in Renal Cell Carcinoma. Arch Pathol Lab Med, 131, 261-7. - Tian SJ, Cheng L, Xu ZH, et al (2011). Relationship of renal cell carcinoma angiogenesis with heparanase and cyclooxygenase-2. J Shadong Univ, 49, 135-9.
- Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z (2004). Significance of COX-2 expression in human renal cell carcinoma. Urol, 64, 1116-20. https://doi.org/10.1016/j.urology.2004.07.023
- Wang X, Zhang L, O'Neill A, et al (2013). Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer, 108, 319-26. https://doi.org/10.1038/bjc.2012.591
- Yoshimura R, Matsuyama M, Kawahito Y, et al (2004). Study of cyclooxygenase-2 in renal cell carcinoma. Int J Mol Med, 13, 229-33.
피인용 문헌
- miR-433 protects pancreatic β cell growth in high-glucose conditions vol.16, pp.3, 2017, https://doi.org/10.3892/mmr.2017.6925